Literature DB >> 30059128

The impact of admission cystatin C levels on in-hospital and three-year mortality rates in acute decompensated heart failure.

Hatice Selcuk1, Mehmet Timur Selcuk1, Orhan Maden1, Kevser Gülcihan Balci2, Mustafa Mücahit Balci1, Sebahat Tekeli1, Elif Hande Çetin1, Ahmet Temizhan1, Mustafa Balci3, Nihal Karabiber4.   

Abstract

BACKGROUND: Although tremendous advances have been made in preventative and therapeutic approaches in heart failure (HF), the hospitalisation and mortality rates for patients with HF is high. The aim of this study was to investigate the association between cystatin C and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and in- and out-of-hospital mortality rates in acute decompensated HF (ADHF).
METHODS: Between February 2008 and November 2011, 57 consecutive patients who were admitted with ADHF were included in this prospective study. These patients were clinically followed up every three months by means of visits or telephone interviews. The primary clinical endpoint of this study was any death from heart failure rehospitalisation and/or other causes.
RESULTS: The subjects who died during the in-hospital follow up were younger than the survivors (47.4 ± 17.5 vs 60.8 ± 15.8, p = 0.043). There was a notable correlation between plasma cystatin C and NT-proBNP levels (r = 0.324, p = 0.014) and glomerular filtration rate (GFR) (r = -0.638, p < 0.001). Multivariate logistic regression analysis revealed that only cystatin C level [odds ratio (OR): 12.311, 95% confidence interval (CI): 1.616-93.764, p = 0.015] and age [OR: 0.925, 95% CI: 0.866-0.990, p = 0.023] were linked to in-hospital mortality rate. In the multivariate Cox proportional hazard model, only admission sodium level appeared as a significant independent predictor of death during the 36-month follow up [hazard ratio: 0.937, 95% CI: 0.880-0.996, p = 0.037].
CONCLUSION: Evaluation of admission cystatin C levels may provide a reliable prediction of in-hospital mortality, compared to estimated GFR or NT-proBNP levels among patients with ADHF. However, in this trial, during long-term follow up, only admission sodium level significantly predicted death.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30059128      PMCID: PMC8962714          DOI: 10.5830/CVJA-2018-035

Source DB:  PubMed          Journal:  Cardiovasc J Afr        ISSN: 1015-9657            Impact factor:   1.167


  26 in total

1.  Cystatin C-based CKD-EPI equations and N-terminal pro-B-type natriuretic peptide for predicting outcomes in acutely decompensated heart failure.

Authors:  Pedro J Flores-Blanco; Sergio Manzano-Fernández; Juan I Pérez-Calvo; Francisco J Pastor-Pérez; Francisco J Ruiz-Ruiz; Francisco J Carrasco-Sánchez; José L Morales-Rull; Domingo Pascual-Figal; Luis Galisteo-Almeda; James L Januzzi
Journal:  Clin Cardiol       Date:  2015-02-06       Impact factor: 2.882

2.  Guidelines for treatment of acute heart failure (JCS 2011).

Authors: 
Journal:  Circ J       Date:  2013-06-12       Impact factor: 2.993

Review 3.  The cardiorenal syndrome in heart failure.

Authors:  Kevin Damman; Adriaan A Voors; Gerjan Navis; Dirk J van Veldhuisen; Hans L Hillege
Journal:  Prog Cardiovasc Dis       Date:  2011 Sep-Oct       Impact factor: 8.194

4.  BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria.

Authors:  B G Bruneau; L A Piazza; A J de Bold
Journal:  Am J Physiol       Date:  1997-12

5.  Prognostic significance of changes in cystatin C during treatment of acute cardiac decompensation.

Authors:  Hideaki Inazumi; Satoshi Koyama; Yohei Tanada; Hisayoshi Fujiwara; Yoshiki Takatsu; Yukihito Sato
Journal:  J Cardiol       Date:  2015-06-15       Impact factor: 3.159

Review 6.  Role of biomarkers in the diagnosis and prognosis of acute kidney injury in patients with cardiorenal syndrome.

Authors:  Pam R Taub; Kelly C Borden; Arrash Fard; Alan Maisel
Journal:  Expert Rev Cardiovasc Ther       Date:  2012-05

7.  Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance.

Authors:  Marco Metra; Savina Nodari; Giovanni Parrinello; Tania Bordonali; Silvia Bugatti; Rossella Danesi; Benedetta Fontanella; Carlo Lombardi; Patrizia Milani; Giulia Verzura; Gadi Cotter; Howard Dittrich; Barry M Massie; Livio Dei Cas
Journal:  Eur J Heart Fail       Date:  2008-02       Impact factor: 15.534

8.  N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.

Authors:  Paulo Bettencourt; Ana Azevedo; Joana Pimenta; Fernando Friões; Susana Ferreira; António Ferreira
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

9.  Cystatin C provides more information than other renal function parameters for stratifying risk in patients with acute coronary syndrome.

Authors:  José M García Acuña; Eva González-Babarro; Lilian Grigorian Shamagian; Carlos Peña-Gil; Rafael Vidal Pérez; Ana M López-Lago; Mario Gutiérrez Feijoó; José R González-Juanatey
Journal:  Rev Esp Cardiol       Date:  2009-05       Impact factor: 4.753

10.  Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial.

Authors:  Mihai Gheorghiade; Joseph S Rossi; William Cotts; David D Shin; Anne S Hellkamp; Ileana L Piña; Gregg C Fonarow; Teresa DeMarco; Daniel F Pauly; Joseph Rogers; Thomas G DiSalvo; Javed Butler; Joshua M Hare; Gary S Francis; Wendy Gattis Stough; Christopher M O'Connor
Journal:  Arch Intern Med       Date:  2007-10-08
View more
  2 in total

Review 1.  Synthesizing Markers of Kidney Injury in Acute Decompensated Heart Failure: Should We Even Keep Looking?

Authors:  Alexander S Manguba; Xavier Vela Parada; Steven G Coca; Anuradha Lala
Journal:  Curr Heart Fail Rep       Date:  2019-12

Review 2.  Novel Biomarkers of Renal Dysfunction and Congestion in Heart Failure.

Authors:  Agata Zdanowicz; Szymon Urban; Barbara Ponikowska; Gracjan Iwanek; Robert Zymliński; Piotr Ponikowski; Jan Biegus
Journal:  J Pers Med       Date:  2022-05-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.